These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 16318433)

  • 21. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent understanding in the treatment of visceral leishmaniasis.
    Rosenthal E; Marty P
    J Postgrad Med; 2003; 49(1):61-8. PubMed ID: 12865573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in development of amphotericin B formulations for the treatment of visceral leishmaniasis.
    Mohamed-Ahmed AH; Brocchini S; Croft SL
    Curr Opin Infect Dis; 2012 Dec; 25(6):695-702. PubMed ID: 23147810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral miltefosine treatment in children with visceral leishmaniasis: a brief review.
    Palumbo E
    Braz J Infect Dis; 2008 Feb; 12(1):2-4. PubMed ID: 18553005
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of visceral leishmaniasis: Indian perspective.
    Agrawal S; Rai M; Sundar S
    J Postgrad Med; 2005; 51 Suppl 1():S53-7. PubMed ID: 16519257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of visceral leishmaniasis in 2004.
    Murray HW
    Am J Trop Med Hyg; 2004 Dec; 71(6):787-94. PubMed ID: 15642973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.
    Sundar S; Goyal AK; More DK; Singh MK; Murray HW
    Ann Trop Med Parasitol; 1998 Oct; 92(7):755-64. PubMed ID: 9924533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.
    Murray HW
    Expert Rev Anti Infect Ther; 2004 Apr; 2(2):279-92. PubMed ID: 15482193
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A severe case of visceral leishmaniasis and liposomal amphotericin B treatment failure in an immunosuppressed patient 15 years after exposure.
    Eichenberger A; Buechi AE; Neumayr A; Hatz C; Rauch A; Huguenot M; Diamantis-Karamitopoulou E; Staehelin C
    BMC Infect Dis; 2017 Jan; 17(1):81. PubMed ID: 28095796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amphotericin B: A drug of choice for Visceral Leishmaniasis.
    Kumari S; Kumar V; Tiwari RK; Ravidas V; Pandey K; Kumar A
    Acta Trop; 2022 Nov; 235():106661. PubMed ID: 35998680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment of visceral leishmaniasis in children].
    Minodier P; Noël G; Blanc P; Uters M; Retornaz K; Garnier JM
    Med Trop (Mars); 2007 Feb; 67(1):73-8. PubMed ID: 17506279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current approaches to visceral leishmaniasis treatment in solid organ transplant recipients.
    Clemente WT; Mourão PHO; Aguado JM
    Expert Rev Anti Infect Ther; 2018 May; 16(5):391-397. PubMed ID: 29737887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
    Chappuis F; Sundar S; Hailu A; Ghalib H; Rijal S; Peeling RW; Alvar J; Boelaert M
    Nat Rev Microbiol; 2007 Nov; 5(11):873-82. PubMed ID: 17938629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 36. Current and emerging medications for the treatment of leishmaniasis.
    Chakravarty J; Sundar S
    Expert Opin Pharmacother; 2019 Jul; 20(10):1251-1265. PubMed ID: 31063412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004.
    Olliaro PL; Guerin PJ; Gerstl S; Haaskjold AA; Rottingen JA; Sundar S
    Lancet Infect Dis; 2005 Dec; 5(12):763-74. PubMed ID: 16310148
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of visceral leishmaniasis.
    Sundar S
    Med Microbiol Immunol; 2001 Nov; 190(1-2):89-92. PubMed ID: 11770119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
    Faucher JF; Morquin D; Reynes J; Chirouze C; Hoen B; Le Moing V
    Parasitol Int; 2016 Oct; 65(5 Pt A):444-6. PubMed ID: 27353022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.